Newsletter · · Ashutosh Agarwal

Novo CEO Calls the Oral Pill Pharma's Best Launch Ever - The GLP-1 Complex - Week of September 14, 2026

The GLP-1 Complex for the week of September 14, 2026. Podcast synthesis on Novo Nordisk's CEO calling the oral Wegovy pill the best pharmaceutical launch ever at 5 million prescriptions in six months, the bull and bear cases from operators and clinicians, and read-throughs across food, sleep apnea, and the peptide grey market.

The GLP-1 Complex

Week of September 14, 2026: Novo CEO Calls the Oral Pill Pharma's Best Launch Ever

Novo Nordisk spent the last year getting punched in the face by Eli Lilly. This week its CEO sat down and made the case that the comeback is already underway, and he brought a number that is hard to argue with. Meanwhile the clinicians and food executives on the week's podcasts kept circling the same question from different angles: how big does this actually get, and who ends up paying for it?

TL;DR

  • Novo's oral pill is selling faster than anything pharma has launched before: 5 million prescriptions in six months, per the CEO on the record.
  • The read-through names keep telling on themselves: the Krispy Kreme and Hershey camps say they see no GLP-1 dent, while sleep-apnea doctors say the next-generation drugs could rival surgery.
  • The bear case this week wasn't about competition, it was about biology and price. Novo's big non-obesity heart drug failed, and clinicians warn that trial-level results won't survive real-world doses and real-world wallets.

What's new

Novo's CEO put a record number on the table. In an on-the-record interview, Novo Nordisk CEO Mike Doustdar told Power Players with Brian Sozzi that the company's oral semaglutide pill (the Wegovy pill) has hit "5 million prescriptions" six months into launch, "the best product launch of any pharmaceutical company to date in volume." He says the pill is taking "9 out of 10 patients that want a pill," with only one in ten going to Lilly's competing pill, orforglipron. This is operator commentary, and it moves the numbers: if 90% of the fast-growing oral market is Novo's, the Street's worry about share loss is being fought on a front where Novo is, for now, winning.

A credible oral fast-follower showed up. On On The Pen, host Dave Knapp walked through fresh data from Structure Therapeutics on its oral GLP-1 (alenaglipron): "up to 16.2% mean weight loss at 72 weeks, with more than one in three patients at the higher dose losing more than 20% of their body weight." That is injectable-level weight loss in a pill, and because it's a non-peptide small molecule, it is cheaper to manufacture, which Knapp argues "could drive the prices lower." The catch: one dose group showed "messy data," with a plateau and even some weight regain. Real, but not clean.

Lilly's retatrutide keeps opening new doors. On Keeping Current, a physician panel reviewed early liver data on Lilly's triple-hormone drug retatrutide: in a 388-patient study, "80% plus relative fat reduction at the higher doses," which one doctor called "something that certainly I didn't think I would see in my lifetime." That points at MASH (fatty liver disease) as a large label beyond weight loss. (MASH is a serious liver condition driven by fat build-up; there are very few good drugs for it.)

The kids' data is a genuine expansion of the market, and a genuine ethical minefield. On On The Pen, Knapp detailed a Phase 3 trial in children aged 6 to 11: after 68 weeks, "40.4% of the children receiving semaglutide were no longer classified as having obesity," versus 0% on placebo, with more than 85% starting at severe obesity. Both groups got diet-and-exercise support; the drug was the difference. Expect a long public fight, and a larger eventual treatable population.

The debate

The bull case (voiced by operators this week): The market is still tiny relative to the disease. Novo's Doustdar noted the US has "around 110 million people suffering from obesity" and only "15, 20 million" are on any GLP-1, globally about 25 million. His point to nervous food executives who say they see no impact yet: "there's a timing effect here... still a fraction." In other words, the demand story has barely started. And the drugs keep finding new jobs: sleep apnea doctors on BackTable ENT & Allergy said tirzepatide (Zepbound) already cuts the apnea-hypopnea index (the standard measure of how many times an hour you stop breathing in your sleep) by "55% to 60%," and that next-gen triple agonists could push that to "65 to 70%," making them "almost as good as bariatric surgery."

The bear case (voiced by clinicians and academics this week): Biology and price are the ceiling, not competition. On Health & Veritas, Yale cardiologist Dr. Harlan Krumholz laid out Novo's ZEUS trial, a big bet that an anti-inflammation drug would cut heart attacks in more than 6,300 patients. It didn't: "cardiovascular events did not [fall]. A hazard ratio of 0.99" (meaning no benefit over placebo), and Novo halted two related heart-failure trials. His verdict: "this is a company that bet big and for the moment is losing... it's not easy to be successful." The price wall is the other half: on The Plus SideZ, clinicians noted the UK recently limited tirzepatide on its public system because "they couldn't afford to pay for them for all the people," and that it's "actually hard to show cost effectiveness for these medications" at current prices.

Read-throughs

Food and snacks, the operators keep saying "no dent." On Welcome to the Arena, Krispy Kreme CEO Josh Charlesworth was blunt: "we're not seeing significant impact specifically from the GLP-1s," and said GLP-1 customers are "just as if not more discerning" on quality. On the consumer side, the hosts of The Best One Yet noted Americans spent "$250 million... on Hershey's chocolate for s'mores, which is up 9% from the year before... despite Ozempic." Two data points, same direction: the confection demand-destruction short has not shown up in the numbers yet. Note both are self-interested sources, and Novo's own CEO argues the impact is simply early.

Sleep apnea (RMD, INSP), the most double-edged read-through. The same BackTable doctors who are excited about GLP-1s for their patients are describing a world where enough weight loss gets people "off CPAP" entirely. That is great medicine and a real question mark for the CPAP franchise, even as it expands the number of diagnosed, treatable patients.

Compounding and the grey market. On The Natural List, a supplements editor tied the boom in unregulated peptides directly to drug prices: the "incredibly inaccessible pricing for these pharmaceutical GLP-1s" is pushing people toward "cheaper options that aren't regulated." The peptide supplement market alone is pegged at "roughly 4 billion in 2026" heading to "6 billion by 2030," a reminder that the shortage era created habits, and habits are sticky.

What we couldn't cover this week

The podcasts were quiet on several corners of the complex this week: no meaningful discussion of the injectable fast-followers (Viking, Amgen's MariTide, Roche, Pfizer, AstraZeneca), and nothing usable on the pharmacy-benefit managers (CVS Caremark, Express Scripts, OptumRx) or on rebates and Medicare coverage.